Cor Therapeutics Inc. announced Tuesday that it has filed aregistration statement with the Securities and ExchangeCommission for a follow-on public offering of 3 million sharesof common stock.
The underwriters, Robertson, Stephens & Co. L.P. andMontgomery Securities, have the option to purchase 450,000additional shares to cover overallotments.
Cor Therapeutics (NASDAQ:CORR) of South San Francisco, Calif.,raised about $40.7 million in an offering of 2.9 million shares ofcommon stock in January and $15 million in its initial publicoffering in June 1991.
The company is beginning a Phase III trial of its lead product,the platelet inhibitor Integrelin, for use in the setting ofcoronary angioplasty. Cor has also completed a Phase II studyof Integrelin for treatment of unstable angina.
Cor's stock closed at $17 a share on Tuesday, up $1.75.
(c) 1997 American Health Consultants. All rights reserved.